Business Context and Reporting Period
This Form 8-K is filed by Obalon Therapeutics, Inc. (trading symbol: OBLN), not Vyome Holdings, Inc. The report covers the financial results for the quarter and full year ended December 31, 2019, announced on February 27, 2020. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) for detailed data. Consequently, specific numerical values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this text. The filing does not provide a clear value for any financial metric.
Material Changes
The filing text does not contain specific data regarding material changes versus prior periods. It only confirms that results for the period ended December 31, 2019, have been reported.
Guidance, Outlook, and Risks
The text does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It explicitly states that the information furnished (including the press release) is not deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings.
Investor Verification Checklist
- Verify the correct registrant name: Obalon Therapeutics, Inc. (OBLN), as the input metadata incorrectly listed Vyome Holdings, Inc.
- Locate and review Exhibit 99.1 (Press Release dated February 27, 2020) to obtain actual revenue, net loss, and cash position figures.
- Confirm the company's status as an emerging growth company and any associated election regarding extended transition periods for accounting standards.
- Note that the financial data in the press release is furnished but not "filed" under Section 18 of the Exchange Act.